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Abstract
Background: The recent study described a better outcome in acute promyelocytic leukemia patients treated with
all-trans retinoic acid and arsenic oxide compared to those treated with all-trans retinoic acid combined with
conventional chemotherapy. The pivotal study indicated that favorable-risk acute promyelocytic leukemia patients
can be cured without any cytotoxic chemotherapy. Even high-risk patients are treatable with cytotoxic agents.
Acute promyelocytic leukemia does not develop only by the dedifferentiation caused by PML-RARA. A determined
oncogene other than PML-RARA which promotes cell proliferation would be required.
Case presentation: We recently treated a 30-year-old Japanese female who achieved molecular remission with
only the administration of all-trans retinoic acid. The patient’s leukemic clones concomitantly had a del(5q) aberrant
chromosome with t(15;17) (q22;q12). The patient’s bone marrow cells indicated clonal evolution of the tumor cells
expressing CD13dim, CD33+, CD117+, and lacking HLA-DR, CD34 and CD11b. A fluorescence in situ hybridization
analysis detected PML-RARA fusion genes in the patient’s bone marrow specimens, leading to the diagnosis of acute
promyelocytic leukemia.
Conclusion: A del(5q) is one of the characteristic chromosomal abnormalities observed in myelodysplastic
syndrome. On the other hand, up to 40 % of acute promyelocytic leukemia cases are known to harbor the addition
of a clonal cytogenetic abnormality. However, such a case acute promyelocytic leukemia with del(5q) would be
rare, rather than myelodysplastic syndrome, consequently obtaining t(15;17). Which cytogenetic abnormalities, acute
promyelocytic leukemia or myelodysplastic syndrome, came first is informative to make a clinical decision for the
initial therapy. In this case, we speculated the PML-RARA translocation is an original pathogenesis and thereafter
additional cytogenetic abnormalities (del(5q) and -6) common in myelodysplastic syndrome. All-trans retinoic acid
lead the patient into molecular remission. We propose that an assessment of additional cytogenetic abnormality in
acute promyelocytic leukemia would contribute to the clinical decisions regarding whether to treat disease with all-
trans retinoic acid and cytotoxic agents. It would be of interest to know the extent of cytogenetic abnormality in
the patients regarding to mixed leukemia. One or more additional cytogenetic abnormalities other than PML-RARA
could account for the biological malignant grade and prognostic index.
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Background
Up to 40 % of patients with acute promyelocytic leukemia
(APL) have an additional chromosomal abnormality other
than PML-RARA [1], recognized as secondary cytogenetic
abnormalities; +8 is the most frequent (10 %–15 %). The
WHO 2008 criteria for the diagnosis of myelodysplastic
syndrome (MDS) note that dysplasia in one or more
lineages is essential and required for the diagnosis of
MDS, and that the observation of several clonal
chromosomal abnormalities, although frequent, is
merely a supportive finding [1]. The presence of recur-
ring chromosomal abnormalities as the sole finding in
the absence of morphological changes is not considered
definitive evidence of MDS.
The recurring chromosomal abnormalities character-
ized in MDS include +8, −7 or del(7q) −5 or del(5q),
del(20q), −Y and others. Recurrent genetic abnormalities
including t(15;17)(q22;q12) are the basis for categorizing
a case as exclusively acute myeloid leukemia (AML).
This means that any APL cases confirmed by the detec-
tion of t(15;17)(q22;q12) with myelodysplastic changes
should be diagnosed as belonging in the AML category.
A precise diagnosis is thus sometimes difficult in APL
cases with morphologic changes such as myelodysplasia
or secondary cytogenetic abnormalities [2].
Indeed, in a large-scale observational study of primary
MDS, the translocation of chromosomes 15 and 17 was
not noted among the 31 AML transformed from MDS
(MDS/AML) [3]. If an individual is diagnosed as having
APL with MDS, a question arises as to which condition
developed first, the APL or the MDS. Myelodysplastic
episodes that precede the onset of APL are linked to a
poor prognosis. If an APL case has additional chromo-
somal abnormalities thereafter during the disease progres-
sion, we would apply the standard treatment for APL,
including all-trans retinoic acid (ATRA) and arsenic oxide
(ATO), agents that result in better outcomes. Thus, be-
cause the diagnosis is critical to the treatment plan, it
would be prudent to determine whether the APL has
evolved from MDS (MDS/APL) and whether the APL
occurred with additional chromosomal abnormalities.
We encountered an APL patient complicated with some
clonal cytogenetic abnormalities including del(5q) and -6.
Case presentation
A 30-year-old Japanese female presented with pancyto-
penia that had gradually progressed over 6 months prior
to the onset. She was afebrile and did not have apparent
abnormal physical examinations. She was referred to a
hematologist for the examination of pancytopenia: her
white blood cell count was 860/μL, hemoglobin 7.8 g/
dL, and platelet 4.0 × 104/μL. This was the so-called ‘pre-
leukemic aplasia’ status. Coagulopathy was revealed by
elevated FDP at 23.6 μg/mL (normal range, 0.0–5.0).
Immediately after her visit to our outpatient hematology
division clinic, we performed bone marrow aspiration,
which revealed a high level of promyelocytes (70.0 %) in
her bone marrow.
A flow cytometry analysis showed that the aberrant
myeloid cells expressed CD13dim, CD33+, CD117+, and
lacked HLA-DR, CD34 and CD11b, leading to the diag-
nosis of APL, and thereafter the detection of PML-RARA
fusion genes by a fluorescence in situ hybridization
(FISH) analysis showed that 97 % of the analyzed cells
bore the targeted fusion gene. This molecular detection
confirmed the APL diagnosis after the initiation of induc-
tion chemotherapy consisting of ATRA [4]. A chromo-
somal analysis during the metaphase revealed that each of
the tumor cells harbored del(5q) or −6 simultaneously
with t(15;17)(q22;q12) (Fig. 1).
Fig. 1 The chromosomal abnormality at the onset. Red squares indicate chromosomal abnormality t(15;17)(q22;q12), and brown rounded squares
indicate del(5q) or −6 found simultaneously in each clone
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The ATRA therapy (45 mg/m2, until disease remission)
resulted in the patient’s cytogenetic complete remission by
45 days after the induction of chemotherapy. The remis-
sion was indicated by the undetectable status of t(15;17)
by chromosomal analysis. At 60 days after the initiation of
ATRA chemotherapy, her cytopenia had recovered to the
normal range. She switched over to an outpatient
clinic on day 57. She achieved molecular remission
proven by no PCR amplification of PML-RARA mRNA
(<3.0 × 106 copy/μg mRNA) at 16 weeks (day 112) with
continuous ATRA treatment. She has maintained
molecular remission as of 2 years.
Conclusions
MDS is a hematological neoplasm that manifests as a few
cytopenia lineage. Clonal cytogenetic aberrations (CCAs)
are found in 30 %–50 % of primary MDS cases. AML
evolving from MDS is a natural course of the disease, but
the FAB classification M3 type conversion overt from
MDS is a relatively rare form [3]. In our patient, ante-
cedent MDS manifestations had been obscure clinically
and morphologically. However, according to the WHO
classification, all cases of AML harboring PML-RARA
should be diagnosed as ‘AML with recurrent genetic
abnormalities,’ even if the case has other chromosomal
abnormalities. Moreover, the recurrent genetic abnor-
malities such as t(8;21)(q22;q22), inv(16)(p13.1q22),
t(15;17)(q22;q12) and t(9;11)(p22;p23) are exclusively
recognized as AML because of the genetic characteris-
tics required for the leukemogenesis.
Regarding the concept of clonal expansion in
hematological oncogenesis, it is conceivable that a com-
mon phenotypic or genetic feature occurs first [5, 6].
According to this logic, the clone with PML-RARA is
original in the present case, and thereafter it obtained
some additional chromosomal abnormalities such as
del(5q) and −6. The concomitant appearance of PML-
RARA and some of the recurring chromosomal abnor-
malities that characterize MDS is rare. The current un-
derstanding is that the PML-RARA fusion gene encoding
a chimeric protein is required but not sufficient for
leukemogenesis [7]. The molecular pathogenesis sup-
ports the hypothesis that PML-RARA rearrangement is
one of the favorable molecular markers [8]. A truncated
granulocyte-macrophage colony-stimulating factor (GM-
CSF) allele on a 5q chromosome had been known in
acute promyelocytic leukemia cell line, HL-60 [9]. This
molecular pathology extends in a loss of other genes lo-
cated on 5q chromosome, such as IL-3, IL-4, IL-5, and
GM-CSF [10]. Those growth factor and cytokines are
critical to differentiation within the lineage of the
leukemic stem cell which carries del(5q) [10]. Then
acute promyelocytic leukemia with del(5q) might have
good prognosis compared to acute promyelocytic
leukemia without del(5q). This should be determined in
the clinical observation.
On the other hand, it is well recognized that therapy-
related secondary hematological malignancies commonly
occur after the remission of APL. The reported inci-
dence of subsequent MDS or AML in patients treated
for APL is 6.5 % [11–13]. However, the question of
whether this oncogenesis is therapy-related or is derived
from the genetic fragility of APL itself is under discus-
sion from a molecular pathology point of view [14]. This
fragility could contribute to the genetic fluctuation of
APL [15]. In our patient, nevertheless it is a rare case,
another possibility of explanation for AML etiology
should be considered; AML evolved MDS, and one of
the MDS clones kept containing 5q- molecular alterna-
tion. If so, the patients would be strongly recommend to
undergo stem cell transplantation for the underlying
MDS. In a while, it was reported that secondary APL is
similar to de novo APL and should be considered distinct
from other secondary acute myeloid neoplasms [16]. In
our patient, ATRA treatment easily led to a complete
molecular remission. Fortunately, 5-azacitidine and lenali-
domide appear to be effective for such patients, but not all
cases of APL with an additional chromosomal abnormality
including variant APL are successfully treated with ATRA
[17, 18].
We speculate that potential leukemogenesis could be
anticipated in APL patients throughout their lives, presum-
ably underlying the genetic instability of hematopoietic
stem cells. Our review of all the rare cases cited herein
[2, 17, 18] indicates that a further aggregation of APL
cases with additional chromosomal abnormalities is
needed for the determination of the clinical gravity, opti-
mal treatment, and degree of background chromosomal
risk based on the differences in genetic prognosis.
We propose that an assessment of additional CCA in
APL would contribute to the clinical decisions regarding
whether to treat APL with cytotoxic agents. It would be
of interest to know the extent of CCA in the patients
regarding to mixed leukemia. One or more additional
cytogenetic abnormalities other than PML-RARA
could account for the biological malignant grade and
prognostic index.
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